Back to News
Market Impact: 0.2
Myriad Genetics Reaches Analyst Target Price
Source: Nasdaq
Analyst EstimatesAnalyst InsightsMarket Technicals & Flows
Myriad Genetics shares rose above the average 12-month analyst target of $3.31, trading at $3.36 per share. The move places the stock slightly above consensus valuation expectations and could prompt analysts to reassess ratings or price targets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
MYGN0.20
More News
- Lula wins Brazil runoff after prediction markets favored Bolsonaro
- Brazil’s real sinks after Lula’s re-election victory
- One-Day Wipeout Tops 60% For the Hardest-Hit Brazilian Stocks
- Trump says Brazil election looked ’rigged’, defeated Bolsonaro’s party recognizes Lula win
- Japan Exchange Group H1 profit jumps 65% on soaring trading activity
- A shock in Brazil sends stocks plunging, while neoclouds take another hit